ストックスクリーナーアプリを入手
28.21
1.19%
-0.34
アフターアワーズ：
28.21
Tyra Biosciences Inc (TYRA) 最新ニュース
TYRA Q1 2026 Earnings: EPS Miss Amid Pre-Revenue Stage, Stock Gains 5.55%Earnings Seasonality - newsline.com
Tyra Biosciences (TYRA) Surges 5.55% on Strong Volume, Testing Key Resistance LevelsCash Flow Strong Stocks - newsline.com
Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism? - Yahoo Finance
Urothelial Carcinoma Market on Track for Major Expansion - openPR.com
Urothelial Carcinoma Market on Track for Major Expansion by 2036, According to DelveInsight | Bristol-Myers Squibb, Astellas Pharma, Pfizer, Johnson & Johnson, Pfizer, Tyra Biosciences, Infinity - Barchart.com
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42 - Moomoo
Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says - Moomoo
TYRA Maintains Rating by B of A Securities -- Price Target Raised to $42 - GuruFocus
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.8, Implies 96% Upside - TradingView
BofA Securities Raises Price Target on Devon Energy to $42 From $37, Buy Rating Kept - marketscreener.com
BofA raises Tyra Biosciences stock price target on safety outlook By Investing.com - Investing.com Nigeria
Analyst Initiates Buy on Tyra Biosciences, Citing De-Risked Dabogratinib Program and Attractive Entry Ahead of Key Bladder Cancer Data - TipRanks
BofA raises Tyra Biosciences stock price target on safety outlook - Investing.com
TYRA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Tyra Biosciences (TYRA) Declines 1.67% as Stock Tests Key Support LevelsCovered Call Trade - newsline.com
Raymond James reiterates Strong Buy on Tyra Biosciences stock amid recent weakness - Investing.com Canada
TYRA: Dabogratinib advances in three FGFR3-driven indications, with pivotal data readouts ahead - TradingView
Tyra Biosciences Shareholders Reelect Directors and Ratify Auditor - TipRanks
Tyra Biosciences (NASDAQ: TYRA) details 2026 shareholder meeting voting outcomes - Stock Titan
Tyra Biosciences (TYRA) director option grant tied to RA Capital funds - Stock Titan
Tyra Biosciences (TYRA) director awarded 13,160 stock options at $32.68 strike - Stock Titan
Tyra Biosciences (TYRA) director granted 13,160 stock options at $32.68 - Stock Titan
Tyra Biosciences (TYRA) director option grant held for RA Capital funds - Stock Titan
Tyra Biosciences (NASDAQ: TYRA) grants 13,160 stock options to director Adele Gulfo - Stock Titan
Director at Tyra Biosciences (NASDAQ: TYRA) awarded stock options - Stock Titan
Tyra Biosciences (TYRA) director granted 13,160 stock options - Stock Titan
[144] Tyra Biosciences, Inc. SEC Filing - Stock Titan
Tyra Biosciences Expands Precision Oncology Clinical Pipeline - asatunews.co.id
Tyra Biosciences Reports Net Loss and Advances Cancer Drug Strategy - HarianBasis.co
Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA) - Yahoo Finance
TYRA Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances Pipeline - newsline.com
Tyra Biosciences (TYRA) Gains 2.23% as Speculative Interest Returns to BiotechKAMA Signal - The Legal Advocate
What's Driving Tyra Biosciences' Recent Surge - Kavout
Tyra Biosciences (TYRA) Advances 2.23% as Stock Closes Near Resistance at $35.08Up Down Ratio - newsline.com
Tyra Biosciences Inc. (TYRA) Faces Modest Decline as Shares Test Key Support ZoneVolume Profile - The Legal Advocate
Tyra Biosciences Inc. (TYRA) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Pipeline Progress ContinuesEarnings Quality Analysis - newsline.com
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
How Tyra Biosciences Inc. (TYRA) Affects Rotational Strategy Timing - Stock Traders Daily
This Tyra Biosciences Insider Reduced Their Stake By 58% - Moomoo
Tyra Biosciences (TYRA) Surges 3.45% as Biotech Momentum BuildsNHNL Ratio - newsline.com
TYRA Pulls Back: Market Rotation Hits Communication - Newser
Tyra Biosciences, Inc. Stock 12‑Month Price Target Raised to $51.78, Implies 59% Upside - TradingView
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - Moomoo
Tyra Biosciences Stock Has a Data Question Investors Can’t Ignore - Bez Kabli
Tyra Biosciences (TYRA) Slips Slightly as Stock Holds Between Key Support and Resistance LevelsBuffered ETF - The Legal Advocate
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY - PR Newswire
Tyra Biosciences (TYRA) Q1 2026 Miss: What Went WrongCommunity Buy Signals - Newser
Wolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendation - MSN
Tyra Biosciences (TYRA) Q1 2026 Disappoints — EPS $-0.64 Below $-0.60 ViewsAnalyst Consensus Shift - Newser
TYRA Initiates Coverage On Wolfe Research -- Rating Set to Peer Perform - GuruFocus
Wolfe Research initiates Tyra Biosciences stock at Peerperform By Investing.com - Investing.com Canada
Wolfe Research Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Hold Rating - Moomoo
Tyra Biosciences Soars 280% in a Year as HighVista Strategies Boosts StakeSenior Analyst Forecasts - Newser
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares - AOL.com
Is Tyra Biosciences’ (TYRA) Dabogratinib 3×3 Focus Reframing Its Risk Reward Profile? - Sahm
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):